摘要
①目的 观察胰腺肿瘤介入化疗术前后相关血清肿瘤标志物糖链抗原 19 9(CA19 9)、糖类抗原 2 4 2(CA2 4 2 )及癌胚抗原 (CEA)的水平变化及其意义。②方法 应用ELISA法检测 4 3例胰腺肿瘤病人介入化疗前后血清CA19 9、CA2 4 2及CEA的水平 ,同时以Karnofsky评分法评价其生活质量变化情况 ,观察治疗后临床受益反应率 (CBRR)。③结果 胰腺肿瘤病人介入化疗后血清CA19 9、CA2 4 2及CEA水平显著降低 ,与治疗前相比差异具有显著性 (F =5 31.2 1～ 5 4 31.0 1,q =13.5 1～ 16 0 .91,P <0 .0 1) ;治疗后病人生活质量明显好转 ,病人Karnofsky评分与化疗前比较差异有显著性 (uc=2 8.4 8,P <0 .0 1)。CBRR为 31.34%。④结论 血清CA19 9、CA2 4
Objective To observe the changes of the levels of serum tumor markers, i.e. CA19-9, CA242 and CEA, and their significance during the interventional chemotherapy for pancreatic carcinoma. Methods ELISA was applied to assay the tumor markers in 43 patients before and after the therapy. The clinical results were evaluated with Karnofsky method. The clinical benefit response rate (CBRR) was also observed. Results The levels of the markers in 43 patients decreased significantly (F=531.21-5 431.01,q=13.51-160.91,P<0.01). The quality of life of the patients improved significantly (u c=28.48, P< 0.01). The CBRR was 31.34%. Conclusion The detection of serum CA19-9, CA242 and CEA is of clinical significance in evaluation of the therapeutic efficacy and patients status.
出处
《齐鲁医学杂志》
2004年第5期414-415,共2页
Medical Journal of Qilu
关键词
胰腺肿瘤
药物疗法
CA19-9抗原
癌胚抗原
pancreatic neoplasms
drug therapy
CA19-9 antigen
carcinoembryonic antigen
